Oral solid dosage forms, including tablets and capsules, dominate the global pharmaceutical market due to OSD convenience and cost-effectiveness. However, manufacturers face numerous challenges in bringing these products to market, including navigating bioequivalence studies, adhering to GMP requirements, and meeting evolving regulatory expectations. Thus, partnering with a Contract Research Organization (CRO) like Zenovel is essential, as it provides integrated solutions encompassing Good Clinical Practice (GCP), GMP, and Regulatory Affairs to support the entire product lifecycle from development to commercialization.
The Unique Challenges Facing OSD Manufacturers
Regulatory Expectations:
Regulatory agencies globally, such as the FDA, EMA, and WHO, are increasingly focusing on data integrity, quality management systems, and risk-based oversight. For manufacturers of oral solid dosage forms (OSD), this necessitates proving compliance throughout the entire development continuum, not merely in manufacturing.
Bioequivalence:
For generic OSD manufacturers, demonstrating bioequivalence is essential for approval. Bioequivalence (BE) studies show that generic drugs release active ingredients similarly to brand-name drugs, measured by pharmacokinetic parameters like AUC and Cmax within 80–125% relative to the reference. Without bioequivalence, generics cannot substitute brand-name drugs, affecting companies’ affordability and availability.
GMP Compliance:
GMP influences all phases of OSD product development, guaranteeing product quality through controlled manufacturing, validation, change management, and documentation. Insufficient GMP frameworks can lead to delays during technology transfer, process validation, stability studies, and regulatory submissions.
The Documentation Expectations
OSD manufacturers need to generate comprehensive documentation during the development lifecycle, including clinical study protocols, reports, CMC documentation, and regulatory submissions. Minor inconsistencies can lead to review delays, regulatory queries, or requests for additional information.
Zenovel Offers CRO Solutions to OSD Manufacturers
Zenovel specializes in high-impact solutions in the pharmaceutical industry, focusing on Good Clinical Practice (GCP), Good Manufacturing Practice (GMP), and Regulatory Affairs. With extensive industry experience and a global presence in India, the USA, Canada, and the EU, Zenovel offers unmatched expertise in its engagements.
GCP Services for Clinical Development Excellence
Zenovel provides comprehensive clinical trial services across all phases (I to IV), including bioequivalence (BE) and pharmacokinetic (PK) studies tailored to client needs. Key capabilities feature Risk-Based Monitoring (RBM) for efficient trial processes and enhanced patient safety, PK-Stat Review for converting data into regulatory evidence, and independent Clinical Monitoring to ensure GCP adherence. With GCP monitoring engagements and extensive experience in trial oversight, Zenovel also assists in CRO setup, process optimization, and regulatory compliance.
Zenovel provides a comprehensive suite of clinical trial services spanning Phase I to Phase IV, which includes patient-focused bioequivalence (BE) and pharmacokinetic (PK) studies, along with customized therapeutic research to fulfill unique client requirements.
GMP Compliance Services for Manufacturing Excellence
Zenovel specializes in the design of GMP-compliant pharmaceutical and biotech projects, leveraging expertise in regional resources and regulatory requirements. Key capabilities include conducting GMP audits across various countries, offering consulting services to expedite drug development while ensuring compliance, guiding GMP plant setup and upgrades per international quality standards, managing documentation control, and validating computerized systems for regulatory adherence.
Regulatory Affairs for Global Pathway Navigation
Zenovel’s regulatory team specializes in navigating the regulatory landscape, offering services to ensure timely submissions with compliance documents. Key capabilities include preparation and submission of Marketing Authorisation Applications (MAAs) and post-approval submissions; support for product registration in major bodies like the USA, Europe, and WHO, expertise in eCTD software for EU and US submissions; gap assessments for various markets, and regulatory strategy design by experts with years of experience.
CMC Development Services
Zenovel provides comprehensive Chemistry, Manufacturing, and Controls (CMC) development services tailored for the pharmaceutical and biotechnology sectors. Our key capabilities include: Preformulation studies focus on physicochemical characterization, solubility and stability testing, excipient compatibility, and analytical method development. Formulation development involves creating and optimizing various dosage forms, including solid, liquid, and injectable forms, along with prototype development. Scale-up and technology transfer cover pilot plant scale-up, process validation, and regulatory compliance in manufacturing. Quality by Design (QbD) incorporates risk assessment, Design of Experiments (DOE), Process Analytical Technology (PAT), and developing control strategies. Product launch support includes preparing regulatory dossiers and market launch planning, as well as post-launch monitoring. Batch release and testing ensure GMP-certified importation, batch testing, and release of medicinal products. Stability studies conduct GMP-certified ICH stability assessments on products like tablets, capsules, and injectables.
Pre-Inspection Readiness
Zenovel prepares facilities and staff for FDA and regulatory inspections, addressing gaps proactively to minimize regulatory findings and ensure compliance. With a global team and local expertise, Zenovel combines regulatory knowledge with market insights. Our philosophy emphasizes exceeding industry standards, supported by a proven track record in clinical monitoring, audits, and regulatory submissions. Zenovel offers end-to-end support throughout the product lifecycle, from CMC development and clinical trials to post-approval compliance.
Are you ready to accelerate your oral solid dosage development program? Contact us today to learn how our comprehensive CRO solutions can support your next product launch.
